Next Article in Journal
Effects of Respiratory Muscle Training on Baroreflex Sensitivity, Respiratory Function, and Serum Oxidative Stress in Acute Cervical Spinal Cord Injury
Previous Article in Journal
Association between HOTAIR lncRNA Polymorphisms and Coronary Artery Disease Susceptibility
Open AccessReview

Design and Analysis of Cancer Clinical Trials for Personalized Medicine

Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27710, USA
Academic Editor: Lorenza Rimassa
J. Pers. Med. 2021, 11(5), 376; https://doi.org/10.3390/jpm11050376
Received: 7 April 2021 / Revised: 22 April 2021 / Accepted: 22 April 2021 / Published: 4 May 2021
(This article belongs to the Section Epidemiology)
Biomarkers play a key role in the development of personalized medicine. Cancer clinical trials with biomarker should be appropriately designed and analyzed reflecting the various factors, such as the phase of trials, the type of biomarker, the study objectives, and whether the used biomarker is already validated or not. In this paper, we demonstrate design and analysis of two phase II cancer clinical trials, one with a predictive biomarker and the other with a prognostic biomarker. A statistical testing method and its sample size calculation method are presented for each of the trials. We assume that the primary endpoint of these trials is a time to event variable, but this concept can be used for any type of endpoint with associated testing methods. The test statistics and their sample size formulas are derived using the large sample approximation based on the martingale central limit theorem. Using simulations, we find that the test statistics control the type I error rate accurately and the sample sizes calculated using the formulas maintain the statistical power specified at the design stage. View Full-Text
Keywords: enrichment trial; interaction; predictive biomarker; prognostic biomarker; progression-free survival; stratified randomization trial enrichment trial; interaction; predictive biomarker; prognostic biomarker; progression-free survival; stratified randomization trial
MDPI and ACS Style

Jung, S.-H. Design and Analysis of Cancer Clinical Trials for Personalized Medicine. J. Pers. Med. 2021, 11, 376. https://doi.org/10.3390/jpm11050376

AMA Style

Jung S-H. Design and Analysis of Cancer Clinical Trials for Personalized Medicine. Journal of Personalized Medicine. 2021; 11(5):376. https://doi.org/10.3390/jpm11050376

Chicago/Turabian Style

Jung, Sin-Ho. 2021. "Design and Analysis of Cancer Clinical Trials for Personalized Medicine" J. Pers. Med. 11, no. 5: 376. https://doi.org/10.3390/jpm11050376

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop